Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).
J Leukoc Biol
; 94(6): 1201-6, 2013 Dec.
Article
em En
| MEDLINE
| ID: mdl-23695306
ABSTRACT
NSCLC remains one of the most challenging malignancies to treat. Despite the introduction of innovative therapies over the last decade, the 5-year survival of NSCLC is still <20%. Clearly, novel, therapeutic approaches are required. Targeting the immune system to derive meaningful clinical benefit has proved successful in various malignancies in recent years. As a result, there is renewed focus on the use of immunotherapy in lung cancer. In this review, we provide an overview of current immune-modulatory approaches in the treatment of NSCLC.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Imunoterapia
/
Neoplasias Pulmonares
Limite:
Humans
Idioma:
En
Revista:
J Leukoc Biol
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Reino Unido
País de publicação:
ENGLAND
/
ESCOCIA
/
GB
/
GREAT BRITAIN
/
INGLATERRA
/
REINO UNIDO
/
SCOTLAND
/
UK
/
UNITED KINGDOM